製品の概要

  • 製品名Human FOXE3 peptide

製品の詳細

  • 由来Synthetic
  • アミノ酸配列
    • 生物種Human
    • 配列AGRSDMDPPAAFS-C
    • 領域2 to 14

特性

Our Abpromise guarantee covers the use of ab23063 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • アプリケーション

    Blocking

  • 製品の状態Liquid
  • Concentration information loading...

前処理および保存

  • 保存方法および安定性

    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

関連情報

  • 別名
    • Drosphilia Forkhead Homolog Like 12
    • FKHL 12
    • FKHL12
    • Forkhead Box E3
    • Forkhead box protein E3
    • Forkhead Related Activator 8
    • Forkhead related protein FKHL12
    • Forkhead-related protein FKHL12
    • Forkhead-related transcription factor 8
    • Foxe3
    • FOXE3 forkhead box E3
    • FOXE3_HUMAN
    • FREAC 8
    • FREAC-8
    • FREAC8
    see all
  • 関連疾患Defects in FOXE3 are a cause of anterior segment mesenchymal dysgenesis (ASMD) [MIM:107250]; also known as anterior segment ocular dysgenesis (ASOD). ASMD consists of a range of developmental defects in structures at the front of the eye, resulting from abnormal migration or differentiation of the neural crest derived mesenchymal cells that give rise to the cornea, iris, and other components of the anterior chamber during eye development. Mature anterior segment anomalies are associated with an increased risk of glaucoma and corneal opacity. Conditions falling within the phenotypic spectrum include aniridia, posterior embryotoxon, Axenfeld anomaly, Reiger anomaly/syndrome, Peters anomaly, and iridogoniodysgenesis.
    Defects in FOXE3 are a cause of congenital primary aphakia (CPA) [MIM:610256]. Aphakia is a rare congenital eye disorder in which the lens is missing. It has been histologically subdivided into primary and secondary forms, in accordance with the severity of defects of the ocular tissues, whose development requires the initial presence of a lens. CPA results from an early developmental arrest, around the 4th-5th week of gestation in humans, that prevents the formation of any lens structure and leads to severe secondary ocular defects, including a complete aplasia of the anterior segment of the eye. In contrast, in secondary aphakic eyes, lens induction has occurred, and the lens vesicle has developed to some degree but finally has progressively resorbed perinatally, leading, therefore, to less-severe ocular defects.
  • 配列類似性Contains 1 fork-head DNA-binding domain.
  • 発生段階Expressed in the lens during embryonic development. Predominantly expressed in the anterior lens epithelium but with some expression posteriorly. Not expressed in brain in embryos.
  • 細胞内局在Nucleus.
  • Information by UniProt

Human FOXE3 peptide (ab23063) 使用論文

ab23063 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab23063.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"